Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (91-100 of 209) with videos related to

Pageof 21
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|January 28, 2019
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims DatabaseArnaud Bourdin, Caroline Fabry-Vendrand, Juliette Ostinelli, et al.
Pathology, Research and Practice|December 15, 2019
Evaluation of the Idylla system to detect the EGFR<sup>T790M</sup> mutation using extracted DNAClaire Bocciarelli, Justine Cohen, Romain Pelletier, et al.
Respiratory Medicine and Research|December 30, 2025
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in FranceMaurice Pérol, Clarisse Audigier-Valette, Hervé Léna, et al.
Targeted Oncology|February 28, 2022
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysisSuzy Van Sanden, Molly Murton, Anna Bobrowska, et al.
Clinical Lung Cancer|December 4, 2014
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501Radj Gervais, Hervé Le Caer, Isabelle Monnet, et al.
Scientific Reports|June 7, 2018
Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling ApproachLaurent Boyer, Sylvie Bastuji-Garin, Christos Chouaid, et al.
Advances in Therapy|June 3, 2019
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14Jean-Bernard Auliac, Pascal Dô, Sophie Bayle, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Current Medical Research and Opinion|January 26, 2019
Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in FranceChristos Chouaid, Nicola Germain, Gérard De Pouvourville, et al.
Pageof 21

Showing results (91-100 of 209) with videos related to

Sort By:
Pageof 21
The Journal of Allergy and Clinical Immunology. in Practice|January 28, 2019
The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims DatabaseArnaud Bourdin, Caroline Fabry-Vendrand, Juliette Ostinelli, et al.
Pathology, Research and Practice|December 15, 2019
Evaluation of the Idylla system to detect the EGFR<sup>T790M</sup> mutation using extracted DNAClaire Bocciarelli, Justine Cohen, Romain Pelletier, et al.
Respiratory Medicine and Research|December 30, 2025
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in FranceMaurice Pérol, Clarisse Audigier-Valette, Hervé Léna, et al.
Targeted Oncology|February 28, 2022
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysisSuzy Van Sanden, Molly Murton, Anna Bobrowska, et al.
Clinical Lung Cancer|December 4, 2014
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501Radj Gervais, Hervé Le Caer, Isabelle Monnet, et al.
Scientific Reports|June 7, 2018
Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling ApproachLaurent Boyer, Sylvie Bastuji-Garin, Christos Chouaid, et al.
Advances in Therapy|June 3, 2019
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14Jean-Bernard Auliac, Pascal Dô, Sophie Bayle, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Current Medical Research and Opinion|January 26, 2019
Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in FranceChristos Chouaid, Nicola Germain, Gérard De Pouvourville, et al.
Pageof 21